사이토카인 방출 증후군 관리 시장 규모는 향후 몇 년 동안 강력한 성장세를 보일 것으로 예상되며, 2029년까지 6.5%의 CAGR로 306억 9,000만 달러에 달할 것으로 예상됩니다. 예측 기간 동안 성장의 원동력은 진단 도구 및 치료에 대한 수요 증가, 정부 보조금 증가, 효과적인 치료법에 대한 수요 증가, 고령화, 공공 및 민간 기관의 이니셔티브 확대 등이 될 것으로 예상됩니다. 예측 기간의 주요 동향으로는 최소침습적 유방 생검 장비의 개발, 전략적 파트너십 및 제휴, 재택 항생제 주입 서비스, 새로운 약물전달 시스템의 출현, 감염 추적을 위한 전자 의료 기록의 통합 등을 들 수 있습니다.
표적 치료제의 사용 증가는 향후 몇 년 동안 사이토카인 방출 증후군 관리 시장의 성장을 촉진할 것으로 예상됩니다. 표적 치료제는 종양 발생에 관여하는 분자 경로를 표적으로 삼아 암의 성장과 확산을 막기 위해 특별히 고안된 치료법입니다. 표적 치료제의 증가는 주로 건강한 세포에 대한 피해를 최소화하면서 암세포를 정확하게 표적화할 수 있는 능력에 기인하며, 기존 치료법에 비해 치료 효과는 향상되고 부작용은 감소하는 등 CRS의 관리는 CAR-T 세포 치료제, 면역관문억제제 등 치료의 안전성과 유효성을 높이기 위해 심각한 염증 반응을 조절하여 표적 치료를 최적화하는 데 중요한 역할을 하고 있습니다. 예를 들어, 2024년 1월 미국 유전자 및 세포 치료학회(American Society of Gene and Cell Therapy)는 2023년 4분기에 임상 3상 시험 중인 유전자 치료제의 수가 10% 증가했다고 보고했습니다. 이에 따라 표적 치료제의 사용 확대가 사이토카인 방출 증후군 관리 시장의 성장을 견인하고 있습니다.
사이토카인 방출 증후군 관리 시장의 주요 기업들은 숙주 지향성 저분자 약물과 같은 혁신적인 치료법 개발에 주력하고 있으며, 감염이나 암과 싸우는 신체의 능력을 손상시키지 않고 면역 반응을 조절하여 사이토카인 폭풍의 심각성을 감소시키는 것을 목표로 하고 있습니다. 숙주 지향성 저분자 의약품은 숙주의 면역 신호전달 경로를 타겟으로 설계된 저분자 화합물로, 과도한 사이토카인 생성을 억제하고 면역체계의 과잉 활성화를 방지하여 CRS 관리에 도움을 줄 수 있습니다. 예를 들어, 2025년 4월 미국 생명공학 기업 사이토에이전트(CytoAgents Inc.)는 CAR-T 세포 치료 환자의 CRS 예방 및 치료를 위한 숙주 지향성 저분자 약물 CTO1681의 1b/2a상 임상 1b/2a상 시험에서 첫 번째 용량 증량 코호트가 성공적으로 종료되었다고 발표했습니다. 이 임상시험에서 CTO1681은 양호한 안전성 프로파일을 보였으며, 용량 제한 독성이나 CAR T 세포의 효능을 저해하지 않았습니다. 현재 진행 중인 임상시험은 CTO1681의 안전성, 내약성, 예비 유효성을 평가하고 권장 2상 용량을 결정하기 위한 것입니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향과 전략
제4장 시장 - 금리, 인플레이션, 지정학, 무역 전쟁과 관세, 그리고 코로나와 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
- 세계 사이토카인 방출 증후군 관리 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
- 최종 이용 산업 분석
- 세계의 사이토카인 방출 증후군 관리 시장 : 성장률 분석
- 세계의 사이토카인 방출 증후군 관리 시장 실적 : 규모와 성장, 2019-2024년
- 세계의 사이토카인 방출 증후군 관리 시장 예측 : 규모와 성장, 2024-2029년, 2034년
- 세계 사이토카인 방출 증후군 관리 전체 시장(TAM)
제6장 시장 세분화
- 세계의 사이토카인 방출 증후군 관리 시장 : 치료 종류별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
- 단클론항체
- 코르티코스테로이드
- 정맥내 면역글로불린(IVIG)
- 표적요법
- 지지요법
- 기타 치료 종류
- 세계의 사이토카인 방출 증후군 관리 시장 : 적응증별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
- 키메라 항원 수용체(CAR) T 세포 치료
- 면역관문억제제
- 조혈모세포 이식(HSCT)
- 자가면역질환
- 감염증
- 기타 적응증
- 세계의 사이토카인 방출 증후군 관리 시장 : 투여 경로별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
- 정맥내(IV)
- 피하(SC)
- 경구
- 근육내(IM)
- 척수내
- 기타 투여 경로
- 세계의 사이토카인 방출 증후군 관리 시장 : 최종사용자별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
- 병원 약국
- 소매 약국
- 온라인 약국
- 전문 클리닉
- 조사기관
- 기타 최종사용자
- 세계의 사이토카인 방출 증후군 관리 시장 : 단클론항체 종류별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
- 토실리주맙
- 실툭시맙
- 인플릭시맙
- 리툭시맙
- 기타 단클론항체
- 세계의 사이토카인 방출 증후군 관리 시장 : 코르티코스테로이드 종류별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
- 덱사메타손
- 프리드니손
- 메틸프레드니솔론
- 하이드로코르티손
- 기타 코르티코스테로이드
- 세계의 사이토카인 방출 증후군 관리 시장 : 정맥내 면역글로불린(IVIG) 종류별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
- 면역글로불린 G(IgG) 기반 정맥내 면역글로불린
- 면역글로불린 A(IgA) 기반 정맥내 면역글로불린
- 면역글로불린 M(IgM) 기반 정맥내 면역글로불린
- 다가 정맥내 면역글로불린
- 기타 종류 정맥내 면역글로불린
- 세계의 사이토카인 방출 증후군 관리 시장 : 표적요법 종류별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
- 야누스 키나아제(JAK) 억제제
- 인터류킨-6(IL-6) 억제제
- 종양괴사인자 알파(TNF-α) 억제제
- 브루톤형 티로신 키나아제(BTK) 억제제
- 기타 표적 에이전트
- 세계의 사이토카인 방출 증후군 관리 시장 : 지지요법 종류별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
- 해열제
- 진통제
- 정맥내 주입과 전해질 용액
- 산소요법
- 혈관 수축약
- 세계의 사이토카인 방출 증후군 관리 시장 : 기타 치료 종류별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
- 혈장 교환 요법(치료적 혈장 교환)
- 항히스타민제
- 백혈구 제거 요법
- 실험적 치료법
- 영양 서포트
제7장 지역별·국가별 분석
- 세계의 사이토카인 방출 증후군 관리 시장 : 지역별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
- 세계의 사이토카인 방출 증후군 관리 시장 : 국가별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 개요
- 사이토카인 방출 증후군 관리 시장 : 경쟁 구도
- 사이토카인 방출 증후군 관리 시장 : 기업 개요
- Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
- Johnson & Johnson Private Limited Overview, Products and Services, Strategy and Financial Analysis
- F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
- AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
- Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
제31장 기타 주요 기업과 혁신적 기업
- Bristol Myers Squibb Company
- Novartis AG
- GlaxoSmithKline plc
- Amgen Inc.
- Gilead Sciences Inc.
- Regeneron Pharmaceuticals Inc.
- Genentech Inc.
- Incyte Corporation
- Swedish Orphan Biovitrum AB
- Biocon Limited
- MacroGenics Inc.
- Legend Biotech Corporation
- Bluebird Bio Inc.
- InflaRx N.V.
- Humanigen Inc.
제32장 세계의 시장 경쟁 벤치마킹과 대시보드
제33장 주요 인수합병
제34장 최근의 시장 동향
제35장 시장 잠재력이 높은 국가, 부문, 전략
- 사이토카인 방출 증후군 관리 시장 2029 : 새로운 기회를 제공하는 국가
- 사이토카인 방출 증후군 관리 시장 2029 : 새로운 기회를 제공하는 부문
- 사이토카인 방출 증후군 관리 시장 2029 : 성장 전략
제36장 부록
ksm
Cytokine release syndrome (CRS) management involves medical strategies to control the excessive immune response caused by an overproduction of cytokines, often seen in conditions such as CAR-T cell therapy or certain infections. The management approach includes medications such as corticosteroids and cytokine inhibitors, supportive care, and, in some cases, intensive monitoring to prevent severe complications. Effective management is critical for reducing the risk of severe organ damage and improving patient outcomes.
The primary treatment options for CRS include monoclonal antibodies, corticosteroids, intravenous immunoglobulin (IVIG), targeted therapy, supportive care, and other treatments. Monoclonal antibodies are laboratory-engineered molecules that target specific cytokines or their receptors to regulate immune activity and manage CRS. These antibodies are used for a range of conditions, including chimeric antigen receptor (CAR) T-cell therapy, immune checkpoint inhibitors, hematopoietic stem cell transplantation (HSCT), autoimmune diseases, infections, and others. They can be administered intravenously (IV), subcutaneously (SC), orally, intramuscularly (IM), intrathecally, or by other methods. These treatments are provided through various channels, including hospital pharmacies, retail pharmacies, online pharmacies, specialty clinics, research institutions, and others.
The cytokine release syndrome management market research report is one of a series of new reports from The Business Research Company that provides cytokine release syndrome management market statistics, including cytokine release syndrome management industry global market size, regional shares, competitors with a cytokine release syndrome management market share, cytokine release syndrome management market segments, market trends, and opportunities, and any further data you may need to thrive in the cytokine release syndrome management industry. This cytokine release syndrome management market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The cytokine release syndrome management market size has grown strongly in recent years. It will grow from $22.32 billion in 2024 to $23.83 billion in 2025 at a compound annual growth rate (CAGR) of 6.8%. Growth during the historic period can be attributed to rising healthcare expenditures, increasing awareness, changing lifestyles, higher disposable incomes, the adoption of personalized medicine approaches, and greater use of targeted therapies.
The cytokine release syndrome management market size is expected to see strong growth in the next few years. It will grow to $30.69 billion in 2029 at a compound annual growth rate (CAGR) of 6.5%. Growth in the forecast period is expected to be driven by increased demand for diagnostic tools and treatments, growing government funding, a rising need for effective therapies, an aging population, and expanding initiatives by both public and private organizations. Key trends in the forecast period include the development of minimally invasive breast biopsy devices, strategic partnerships and collaborations, home-based antibiotic infusion services, the emergence of novel drug delivery systems, and the integration of electronic health records for infection tracking.
The increasing use of targeted therapies is expected to drive the growth of the cytokine release syndrome management market in the coming years. Targeted therapies are treatments specifically designed to block the growth and spread of cancer by targeting molecular pathways involved in tumor development. The rise in targeted therapies is mainly attributed to their ability to precisely target cancer cells while minimizing harm to healthy cells, which improves treatment efficacy and reduces side effects compared to traditional therapies. CRS management plays a vital role in optimizing targeted therapies by controlling severe inflammatory responses, thus enhancing the safety and effectiveness of treatments such as CAR-T cell therapy and immune checkpoint inhibitors. For example, in January 2024, the American Society of Gene and Cell Therapy reported that in the fourth quarter of 2023, the number of gene therapies in Phase III clinical trials increased by 10%, marking the first rise of this kind since the third quarter of 2022. Therefore, the growing use of targeted therapies is fueling the growth of the cytokine release syndrome management market.
Major companies in the cytokine release syndrome management market are focusing on developing innovative therapies, such as host-directed small molecule drugs, which aim to modulate the immune response and reduce the severity of cytokine storms without compromising the body's ability to fight infections or cancer. A host-directed small molecule drug is a low molecular weight compound designed to target immune signaling pathways in the host, helping manage CRS by suppressing excessive cytokine production and preventing immune system overactivation. For instance, in April 2025, CytoAgents Inc., a US-based biotechnology company, announced the successful completion of the first dose-escalation cohort in its Phase 1b/2a clinical trial of CTO1681, a host-directed small molecule drug aimed at preventing and treating CRS in patients receiving CAR T-cell therapy. The investigational therapy showed a favorable safety profile, with no dose-limiting toxicities or disruption to CAR T-cell efficacy. The ongoing trial is designed to assess the safety, tolerability, and preliminary efficacy of CTO1681 and determine the recommended Phase 2 dose.
In March 2024, Merck & Co., Inc., a US-based biopharmaceutical company, acquired Harpoon Therapeutics for $680 million to strengthen its oncology pipeline with innovative T-cell engager therapies. This acquisition integrates Harpoon's T-cell engager technology and lead candidate, MK-6070, currently in a Phase 1/2 trial for advanced cancers, enhancing Merck's immuno-oncology capabilities and expanding its portfolio of next-generation cancer therapies. Harpoon Therapeutics, a clinical-stage biopharmaceutical company, specializes in T-cell engagers for cancer treatment, focusing on its TriTAC-XR platform to reduce CRS and improve treatment efficacy.
Major players in the cytokine release syndrome management market are Pfizer Inc., Johnson & Johnson Private Limited, F. Hoffmann-La Roche Ltd., AbbVie Inc., Sanofi S.A., Bristol Myers Squibb Company, Novartis AG, GlaxoSmithKline plc, Amgen Inc., Gilead Sciences Inc., Regeneron Pharmaceuticals Inc., Genentech Inc., Incyte Corporation, Swedish Orphan Biovitrum AB, Biocon Limited, MacroGenics Inc., Legend Biotech Corporation, Bluebird Bio Inc., InflaRx N.V., and Humanigen Inc.
North America was the largest region in the cytokine release syndrome management market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in cytokine release syndrome management report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the cytokine release syndrome management market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The cytokine release syndrome management market consists of revenues earned by entities by providing services such as diagnostic testing, immunosuppressive therapy, supportive care, clinical trial services, and post-treatment monitoring to manage and treat patients affected by CRS. The market value includes the value of related goods sold by the service provider or included within the service offering. The cytokine release syndrome management market also includes sales of tocilizumab (actemra), siltuximab (sylvant), dexamethasone, ruxolitinib (jakafi), and ivig (intravenous immunoglobulin). Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Cytokine Release Syndrome Management Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on cytokine release syndrome management market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for cytokine release syndrome management ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The cytokine release syndrome management market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
- Markets Covered:1) By Treatment Type: Monoclonal Antibodies; Corticosteroids; Intravenous Immunoglobulin (IVIG); Targeted Therapy; Supportive Care; Other Treatment Types
- 2) By Indication: Chimeric Antigen Receptor (CAR) T-Cell Therapy; Immune Checkpoint Inhibitors; Hematopoietic Stem Cell Transplantation (HSCT); Autoimmune Diseases; Infections; Other Indications
- 3) By Route Of Administration: Intravenous (IV); Subcutaneous (SC); Oral; Intramuscular (IM); Intrathecal; Other Routes Of Administration
- 4) By End Users: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies; Specialty Clinics; Research Institutions; Other End Users
- Subsegments:
- 1) By Monoclonal Antibodies: Tocilizumab; Siltuximab; Infliximab; Rituximab; Other Monoclonal Antibodies
- 2) By Corticosteroids: Dexamethasone; Prednisone; Methylprednisolone; Hydrocortisone; Other Corticosteroids
- 3) By Intravenous Immunoglobulin (IVIG): Immunoglobulin G (IgG)-Based Intravenous Immunoglobulin; Immunoglobulin A (IgA)-Based Intravenous Immunoglobulin; Immunoglobulin M (IgM)-Based Intravenous Immunoglobulin; Polyvalent Intravenous Immunoglobulin; Other Types of Intravenous Immunoglobulin
- 4) By Targeted Therapy: Janus Kinase (JAK) Inhibitors; Interleukin-6 (IL-6) Inhibitors; Tumor Necrosis Factor-Alpha (TNF-a) Inhibitors; Bruton's Tyrosine Kinase (BTK) Inhibitors; Other Targeted Agents
- 5) By Supportive Care: Antipyretic Medications; Analgesic Medications; Intravenous Fluids And Electrolyte Solutions; Oxygen Therapy; Vasopressor Agents
- 6) By Other Treatment Types: Plasmapheresis (Therapeutic Plasma Exchange); Antihistamine Medications; Leukapheresis; Experimental Therapies; Nutritional Support
- Companies Mentioned: Pfizer Inc.; Johnson & Johnson Private Limited; F. Hoffmann-La Roche Ltd.; AbbVie Inc.; Sanofi S.A.
- Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
- Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
- Time series: Five years historic and ten years forecast.
- Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
- Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
- Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
- Delivery Format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Cytokine Release Syndrome Management Market Characteristics
3. Cytokine Release Syndrome Management Market Trends And Strategies
4. Cytokine Release Syndrome Management Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
5. Global Cytokine Release Syndrome Management Growth Analysis And Strategic Analysis Framework
- 5.1. Global Cytokine Release Syndrome Management PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
- 5.2. Analysis Of End Use Industries
- 5.3. Global Cytokine Release Syndrome Management Market Growth Rate Analysis
- 5.4. Global Cytokine Release Syndrome Management Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
- 5.5. Global Cytokine Release Syndrome Management Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
- 5.6. Global Cytokine Release Syndrome Management Total Addressable Market (TAM)
6. Cytokine Release Syndrome Management Market Segmentation
- 6.1. Global Cytokine Release Syndrome Management Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Monoclonal Antibodies
- Corticosteroids
- Intravenous Immunoglobulin (IVIG)
- Targeted Therapy
- Supportive Care
- Other Treatment Types
- 6.2. Global Cytokine Release Syndrome Management Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Chimeric Antigen Receptor (CAR) T-Cell Therapy
- Immune Checkpoint Inhibitors
- Hematopoietic Stem Cell Transplantation (HSCT)
- Autoimmune Diseases
- Infections
- Other Indications
- 6.3. Global Cytokine Release Syndrome Management Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Intravenous (IV)
- Subcutaneous (SC)
- Oral
- Intramuscular (IM)
- Intrathecal
- Other Routes Of Administration
- 6.4. Global Cytokine Release Syndrome Management Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Specialty Clinics
- Research Institutions
- Other End Users
- 6.5. Global Cytokine Release Syndrome Management Market, Sub-Segmentation Of Monoclonal Antibodies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Tocilizumab
- Siltuximab
- Infliximab
- Rituximab
- Other Monoclonal Antibodies
- 6.6. Global Cytokine Release Syndrome Management Market, Sub-Segmentation Of Corticosteroids, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Dexamethasone
- Prednisone
- Methylprednisolone
- Hydrocortisone
- Other Corticosteroids
- 6.7. Global Cytokine Release Syndrome Management Market, Sub-Segmentation Of Intravenous Immunoglobulin (IVIG), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Immunoglobulin G (IgG)-Based Intravenous Immunoglobulin
- Immunoglobulin A (IgA)-Based Intravenous Immunoglobulin
- Immunoglobulin M (IgM)-Based Intravenous Immunoglobulin
- Polyvalent Intravenous Immunoglobulin
- Other Types of Intravenous Immunoglobulin
- 6.8. Global Cytokine Release Syndrome Management Market, Sub-Segmentation Of Targeted Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Janus Kinase (JAK) Inhibitors
- Interleukin-6 (IL-6) Inhibitors
- Tumor Necrosis Factor-Alpha (TNF-a) Inhibitors
- Bruton's Tyrosine Kinase (BTK) Inhibitors
- Other Targeted Agents
- 6.9. Global Cytokine Release Syndrome Management Market, Sub-Segmentation Of Supportive Care, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Antipyretic Medications
- Analgesic Medications
- Intravenous Fluids And Electrolyte Solutions
- Oxygen Therapy
- Vasopressor Agents
- 6.10. Global Cytokine Release Syndrome Management Market, Sub-Segmentation Of Other Treatment Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Plasmapheresis (Therapeutic Plasma Exchange)
- Antihistamine Medications
- Leukapheresis
- Experimental Therapies
- Nutritional Support
7. Cytokine Release Syndrome Management Market Regional And Country Analysis
- 7.1. Global Cytokine Release Syndrome Management Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 7.2. Global Cytokine Release Syndrome Management Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8. Asia-Pacific Cytokine Release Syndrome Management Market
- 8.1. Asia-Pacific Cytokine Release Syndrome Management Market Overview
- Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 8.2. Asia-Pacific Cytokine Release Syndrome Management Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.3. Asia-Pacific Cytokine Release Syndrome Management Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.4. Asia-Pacific Cytokine Release Syndrome Management Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Cytokine Release Syndrome Management Market
- 9.1. China Cytokine Release Syndrome Management Market Overview
- 9.2. China Cytokine Release Syndrome Management Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.3. China Cytokine Release Syndrome Management Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.4. China Cytokine Release Syndrome Management Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Cytokine Release Syndrome Management Market
- 10.1. India Cytokine Release Syndrome Management Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.2. India Cytokine Release Syndrome Management Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.3. India Cytokine Release Syndrome Management Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Cytokine Release Syndrome Management Market
- 11.1. Japan Cytokine Release Syndrome Management Market Overview
- 11.2. Japan Cytokine Release Syndrome Management Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.3. Japan Cytokine Release Syndrome Management Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.4. Japan Cytokine Release Syndrome Management Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Cytokine Release Syndrome Management Market
- 12.1. Australia Cytokine Release Syndrome Management Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.2. Australia Cytokine Release Syndrome Management Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.3. Australia Cytokine Release Syndrome Management Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Cytokine Release Syndrome Management Market
- 13.1. Indonesia Cytokine Release Syndrome Management Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.2. Indonesia Cytokine Release Syndrome Management Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.3. Indonesia Cytokine Release Syndrome Management Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Cytokine Release Syndrome Management Market
- 14.1. South Korea Cytokine Release Syndrome Management Market Overview
- 14.2. South Korea Cytokine Release Syndrome Management Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.3. South Korea Cytokine Release Syndrome Management Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.4. South Korea Cytokine Release Syndrome Management Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Cytokine Release Syndrome Management Market
- 15.1. Western Europe Cytokine Release Syndrome Management Market Overview
- 15.2. Western Europe Cytokine Release Syndrome Management Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.3. Western Europe Cytokine Release Syndrome Management Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.4. Western Europe Cytokine Release Syndrome Management Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Cytokine Release Syndrome Management Market
- 16.1. UK Cytokine Release Syndrome Management Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.2. UK Cytokine Release Syndrome Management Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.3. UK Cytokine Release Syndrome Management Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Cytokine Release Syndrome Management Market
- 17.1. Germany Cytokine Release Syndrome Management Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.2. Germany Cytokine Release Syndrome Management Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.3. Germany Cytokine Release Syndrome Management Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Cytokine Release Syndrome Management Market
- 18.1. France Cytokine Release Syndrome Management Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.2. France Cytokine Release Syndrome Management Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.3. France Cytokine Release Syndrome Management Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Cytokine Release Syndrome Management Market
- 19.1. Italy Cytokine Release Syndrome Management Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.2. Italy Cytokine Release Syndrome Management Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.3. Italy Cytokine Release Syndrome Management Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Cytokine Release Syndrome Management Market
- 20.1. Spain Cytokine Release Syndrome Management Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.2. Spain Cytokine Release Syndrome Management Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.3. Spain Cytokine Release Syndrome Management Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Cytokine Release Syndrome Management Market
- 21.1. Eastern Europe Cytokine Release Syndrome Management Market Overview
- 21.2. Eastern Europe Cytokine Release Syndrome Management Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.3. Eastern Europe Cytokine Release Syndrome Management Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.4. Eastern Europe Cytokine Release Syndrome Management Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Cytokine Release Syndrome Management Market
- 22.1. Russia Cytokine Release Syndrome Management Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.2. Russia Cytokine Release Syndrome Management Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.3. Russia Cytokine Release Syndrome Management Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Cytokine Release Syndrome Management Market
- 23.1. North America Cytokine Release Syndrome Management Market Overview
- 23.2. North America Cytokine Release Syndrome Management Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.3. North America Cytokine Release Syndrome Management Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.4. North America Cytokine Release Syndrome Management Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Cytokine Release Syndrome Management Market
- 24.1. USA Cytokine Release Syndrome Management Market Overview
- 24.2. USA Cytokine Release Syndrome Management Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.3. USA Cytokine Release Syndrome Management Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.4. USA Cytokine Release Syndrome Management Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25. Canada Cytokine Release Syndrome Management Market
- 25.1. Canada Cytokine Release Syndrome Management Market Overview
- 25.2. Canada Cytokine Release Syndrome Management Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.3. Canada Cytokine Release Syndrome Management Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.4. Canada Cytokine Release Syndrome Management Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Cytokine Release Syndrome Management Market
- 26.1. South America Cytokine Release Syndrome Management Market Overview
- 26.2. South America Cytokine Release Syndrome Management Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.3. South America Cytokine Release Syndrome Management Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.4. South America Cytokine Release Syndrome Management Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Cytokine Release Syndrome Management Market
- 27.1. Brazil Cytokine Release Syndrome Management Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.2. Brazil Cytokine Release Syndrome Management Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.3. Brazil Cytokine Release Syndrome Management Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Cytokine Release Syndrome Management Market
- 28.1. Middle East Cytokine Release Syndrome Management Market Overview
- 28.2. Middle East Cytokine Release Syndrome Management Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.3. Middle East Cytokine Release Syndrome Management Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.4. Middle East Cytokine Release Syndrome Management Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Cytokine Release Syndrome Management Market
- 29.1. Africa Cytokine Release Syndrome Management Market Overview
- 29.2. Africa Cytokine Release Syndrome Management Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.3. Africa Cytokine Release Syndrome Management Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.4. Africa Cytokine Release Syndrome Management Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Cytokine Release Syndrome Management Market Competitive Landscape And Company Profiles
- 30.1. Cytokine Release Syndrome Management Market Competitive Landscape
- 30.2. Cytokine Release Syndrome Management Market Company Profiles
- 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Johnson & Johnson Private Limited Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
31. Cytokine Release Syndrome Management Market Other Major And Innovative Companies
- 31.1. Bristol Myers Squibb Company
- 31.2. Novartis AG
- 31.3. GlaxoSmithKline plc
- 31.4. Amgen Inc.
- 31.5. Gilead Sciences Inc.
- 31.6. Regeneron Pharmaceuticals Inc.
- 31.7. Genentech Inc.
- 31.8. Incyte Corporation
- 31.9. Swedish Orphan Biovitrum AB
- 31.10. Biocon Limited
- 31.11. MacroGenics Inc.
- 31.12. Legend Biotech Corporation
- 31.13. Bluebird Bio Inc.
- 31.14. InflaRx N.V.
- 31.15. Humanigen Inc.
32. Global Cytokine Release Syndrome Management Market Competitive Benchmarking And Dashboard
33. Key Mergers And Acquisitions In The Cytokine Release Syndrome Management Market
34. Recent Developments In The Cytokine Release Syndrome Management Market
35. Cytokine Release Syndrome Management Market High Potential Countries, Segments and Strategies
- 35.1 Cytokine Release Syndrome Management Market In 2029 - Countries Offering Most New Opportunities
- 35.2 Cytokine Release Syndrome Management Market In 2029 - Segments Offering Most New Opportunities
- 35.3 Cytokine Release Syndrome Management Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies
36. Appendix
- 36.1. Abbreviations
- 36.2. Currencies
- 36.3. Historic And Forecast Inflation Rates
- 36.4. Research Inquiries
- 36.5. The Business Research Company
- 36.6. Copyright And Disclaimer
